{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang S"],"funding":["National Institute of General Medical Sciences"],"pagination":["20073-20082"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9054207"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(34)"],"pubmed_abstract":["The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is a key enzyme in pathways regulating tumor growth signaling, and recently gained interest as a promising anticancer drug target. Many SHP2 inhibitors are currently under development, including SHP099, which has shown potent anticancer activity at low concentrations <i>in vivo</i>. In this work, we developed multilayer coatings for localized delivery of SHP099 to improve upon current cancer therapies. Layer-by-layer self-assembly was used to develop films composed of chitosan and poly-carboxymethyl-β-cyclodextrin (PβCD) for the delivery of SHP099. SHP099 was successfully loaded into multilayer films <i>via</i> host-guest interactions with PβCD. Nuclear magnetic resonance spectroscopy confirmed the occurrence of thi"],"journal":["RSC advances"],"pubmed_title":["Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy."],"pmcid":["PMC9054207"],"funding_grant_id":["U54GM115677"],"pubmed_authors":["Yang W","Antoci V","Wang S","Alkekhia D","Shukla A","Battigelli A","Fairman A","Moore D"],"additional_accession":[]},"is_claimable":false,"name":"Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.","description":"The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is a key enzyme in pathways regulating tumor growth signaling, and recently gained interest as a promising anticancer drug target. Many SHP2 inhibitors are currently under development, including SHP099, which has shown potent anticancer activity at low concentrations <i>in vivo</i>. In this work, we developed multilayer coatings for localized delivery of SHP099 to improve upon current cancer therapies. Layer-by-layer self-assembly was used to develop films composed of chitosan and poly-carboxymethyl-β-cyclodextrin (PβCD) for the delivery of SHP099. SHP099 was successfully loaded into multilayer films <i>via</i> host-guest interactions with PβCD. Nuclear magnetic resonance spectroscopy confirmed the occurrence of thi","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2025-04-18T14:13:42.261Z","creation":"2025-04-04T20:21:56.906Z"},"accession":"S-EPMC9054207","cross_references":{"pubmed":["35520441"],"doi":["10.1039/d0ra03864d"]}}